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OBJECTIVES: To evaluate the prevalence of cancer and calculate annual health 
care expenditures for patients self-reported with cancer using a large  
US database. METHODS: The 2009 Medical Expenditure Panel Survey, a 
nationally representative survey of the US population was used to evaluate the 
prevalence and health care expenditure for patients self-reported with cancer. 
All patients over 17 years of age and diagnosed with any type of cancer was 
included in the study. The data was descriptively evaluated based on patient 
demographics and insurance type. RESULTS: The total patient population 
identified in this study was 36,855. Of these, 2,113 (5.7%) patients were diagnosed 
with some type of cancer. The study identified 27 different types of cancers  
and the top three highly prevalent cancers were: breast cancer (0.91%), skin non-
melanoma (0.88%) and prostate cancer (0.69%). The cancers that were more 
common in females than in males were bone, larynx, lymphoma, soft tissue, 
pancreas, stomach and thyroid. The mean patient total income reported was 
$29,583±20,696 and the median income was $20,512. The mean total family 
income reported was $56,254±52,729 and the median was $39,646. The highest 
mean total health care charges were for rectum ($92,022±146,618), pancreas 
($64,040±62,297) and leukemia ($54,193±84,300). The mean total amount 
reimbursed by Medicare, Medicaid, and Private Health Insurance for all cancer 
types were $4,719±12,589, $1,209±7,106 and $3,415±11,043 respectively. The  
mean total amount paid by patient out of the total health care charges  
was $1,271±3,342. The mean total percentage paid by Medicare, Medicaid and 
Private Health Insurance out of total health care charges for all cancer types 
were 19.06%, 4.88% and 13.79% respectively. CONCLUSIONS: The prevalence of 
cancer among the overall population was higher than the literature findings. 
Cancer continues to be significant economic burden to both payer and the 
patient.  
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OBJECTIVES: To estimate the cost of PET/CT procedure with 18FDG as its 
radiotracer from the perspective of a Brazilian public provider of health services, 
in order to support economic evaluation studies about the technology. 
METHODS: The micro-costing technique was used, and all inputs consumed in 
the activities involved with the procedure have been identified, measured and 
valuated. This included capital costs, human resources, radiopharmaceutical 
18FDG purchases, administrative costs and others. Data for cost estimates were 
collected from the observation of 85 exams at the Brazilian National Cancer 
Institute (INCA) from March to June 2012. The reference case considered adult 
cancer patients, daily production of 5 exams using one FDG dose per patient. 
INCA employees, because of their research activities, receive differentiated 
wages (from Science and Technology –S&T- career), than the usual employees of 
federal public hospitals where new PET/CTs might be installed receive (from 
Ministry of Health -MoH). So, to avoid biases, two cost estimates were carried out 
considering different wage modalities (MoH and S&T career). Also, sensitivity 
analysis examined elements that might impact on the costs in public health 
institutions. RESULTS: The average costs of the procedure for the reference case 
were US$1612.23 for Science and Technology career’s wages, and US$1498.05 for 
Ministry of Health’s wages. When a scenario of full capacity of exams was 
considered (10 procedures/day), average costs were significantly smaller: 
US$1023.47 for S&T and US$966.38 for MoH. The largest factors of impact on 
costs were daily volume of procedures, human resources, and price of 18FDG. 
CONCLUSIONS: Despite its growing applicability in diagnosis, the technology is 
still complex and aggregate high costs on health system. This is the first study 
which estimates cost of PET/CT technic in Brazil. PET procedure is in the pipeline 
to be reimbursed and this study could contribute to the reference value 
construction.  
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OBJECTIVES: With increasing use and cost of oral oncology medications, patient 
non-adherence with oral therapy is of greater concern. This study sought to 
evaluate the magnitude and predictors of non-adherence among patients 
receiving oral therapy for HCC accounting for patient-level variation in total 
duration of treatment and dose-changes. METHODS: This retrospective cohort 
study used an employer-based, commercially available, large claims database 
(2005-2011) to identify adult patients with ≥ 2 diagnoses of HCC (ICD-9 155), and  
≥2 filled prescriptions for sorafenib - the only approved oral therapy for HCC. 
Additional study inclusion criteria were not having other previous cancers, and a 
3-month wash-out period of no systemic therapy prior to the incident sorafenib 
fill (index) date. Adherence was assessed using a modified Proportion of Days 
Covered (PDC) measure over a patient-specific period from index date to 
treatment discontinuation. Non-adherence was categorized as PDC < 85% (base 
case), with two-way sensitivity analyses using an 80% cut-off and allowance for 
gaps due to dose change/Adverse Events. Logistic models were estimated to 
identify predictors of non-adherence. RESULTS: A total of 1,100 patients (median 
age = 61 years; 78% male) met eligibility criteria. Median sorafenib 30-day co-pay 
was $25 (5% > $500). 25% of patients had prior procedures. Median total sorafenib 
exposure was 120 days (Q1=68; Q3=223). 14.5% and 13.5% patients had down/up-
titrated fills from median index dose of 800 mg/day and 400 mg/day respectively. 
Median PDC was 98%; 15% of patients were non-adherent. Younger (below-
median) age (OR=1.5; p=0.02) and prior procedures (OR=1.7; p=0.003) were robust 
predictors of non-adherence. CONCLUSIONS: Using a modified PDC approach to 
account for varying and relatively short durations of treatment until 
progression/death in HCC, over 15% of patients were found non-adherent. 
Evidence on the predictors of non-adherence should be confirmed in the context 
of other, newly emerging oral therapies and may guide patient education and 
other compliance-enhancing initiatives.  
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OBJECTIVES: Abiraterone acetate is a CYP17 inhibitor indicated for treatment of 
patients with metastatic castration-resistant PC in combination with prednisone. 
The recommended dose is 1000mg (four 250mg tablets) administered once daily 
in combination with prednisone 5mg administered twice daily. This study 
evaluated U.S. real world abiraterone acetate utilization patterns in PC patients 
during the first year of commercial abiraterone acetate availability. METHODS: 
Prometis administrative claims data (6/2009 - 5/2012) were used to identify 
patients with ≥1 PC diagnosis (ICD-9 185.xx, V10.46) and ≥6 months of claims 
activity before their first abiraterone acetate prescription (index date). Population 
characteristics, number of abiraterone acetate fills, daily dose, refill interval, and 
Medication Possession Ratio (MPR) were summarized with descriptive statistics 
(n, %, mean±SD, median). RESULTS: A total of 1,545 PC patients with ≥1 
abiraterone acetate prescription and prerequisite claims activity were identified. 
The majority were ≥65 years of age; 82% were treated by an oncologist; 58% had 
abiraterone acetate claims covered by commercial insurance and 38% by 
Medicare; 49% had ≥6 months of post-index clinical activity. The median 
abiraterone acetate dose was 1,000 mg (mean±SD =995.6±48.6 mg). The median 
refill interval was 29.8 days between dispensings (mean±SD=34.3±16.4 days). 
MPR was 0.96±0.10. CONCLUSIONS: This retrospective study of early abiraterone 
acetate utilization in a large cohort of PC patients showed median abiraterone 
acetate dosing and refill intervals consistent with the product label.  
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OBJECTIVES: Potential for poor medication adherence to oral oncology agents is 
often discussed, but many papers on the subject are review articles and 
treatment periods cited often precede the era of oral tyrosine kinase inhibitors 
(TKIs). Our objective was to assess the landscape of studies published in the era 
of TKIs that assessed real world patient adherence as a main objective. 
METHODS: We searched PubMed in July 2012 for English language papers with 
the following limits applied: English, Humans, Last 10 years and used the MeSH 
terms “medication adherence” and “neoplasms” in addition to separate searches 
using the terms “patient compliance” or “patient adherence” or “patient non-
compliance” or “patient non-adherence” or “non-compliance” or “non-
adherence”and “drug therapy” or “medication”, and “neoplasms” and “oral”. 
RESULTS: Resulting citations (n=595) were searched for primary research articles 
with an objective of assessing adherence in adults taking oral oncolytics outside 
of a clinical trial (n=44). Bibliographies of these studies were reviewed and 
revealed 10 additional studies. Papers not reporting or with poorly described 
methods of assessing adherence were excluded as were those assessing 
adherence by proxy. Of the 54 papers, 43 were included. Over half (58%) included 
patients with breast cancer, 23% with CML, 16% studied multiple tumor types 
and 1 was in gastrointestinal stromal tumor. Data sources consisted mostly (51%) 
of secondary databases with patient self report either verified or unverified also 
common (28%). More than half (56%) were of retrospective cohort design. Most 
studied hormonal therapies (49%), 23% studied TKIs imatinib, dasatinib or 
nilotinib, 21% studied multiple drug classes and 3 studied capecitabine. 
CONCLUSIONS: Since the introduction of oral TKIs, most studies of real world 
adherence to oral oncology agents have been in breast cancer patients and 
studied hormonal therapies. Published studies of adherence to TKIs have 
focused on very few agents.  
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OBJECTIVES: Cancer treatment is rapidly evolving with the emergence of highly 
effective oral targeted therapies, which has elevated the importance of 
adherence. This study examined the rates and effect of real-world non-
adherence from a patient perspective among those using treatments where such 
oral therapies are the standard of care. METHODS: Data from the 2012 U.S. 
National Health and Wellness Survey were analyzed. Patients who reported a 
